A Phase 3 interventional study of Elafibranor 80mg and Placebo in Primary Biliary Cirrhosis, sponsored by Ipsen. Active, not recruiting at 115 sites in 14 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-05.
Sponsored by Ipsen · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Liver Cirrhosis, Biliary by Ipsen — 3 open to participants now, 6 under way, 3 of them phase 3. Liver Cirrhosis, Biliary · Ipsen.
Among the 10 studies in Liver Cirrhosis, Biliary by Ipsen, this one is the only one that started in 2020, is one of 4 in phase 3, and was the 3rd registered.
214 studies on the registry are indexed under Liver Cirrhosis, Biliary; 48 are open to participants now.
Browse Liver Cirrhosis, Biliary studies →3 of the 10 studies in Liver Cirrhosis, Biliary by Ipsen are open now, in 12 countries. Recruiting first, the newest first:
Ipsen · Sites in United States
Women only
Ipsen · Sites in United States, Argentina, Australia and 25 more countries
Ages 18+
Ipsen
Ages 18+
By country, each count listing its studies:
Of the 34 Liver Cirrhosis, Biliary studies recruiting now, 16 (47%) set no upper age limit and 11 (32%) stop at 75 or younger; 3 take children under 18; 4 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2013; this study’s year is marked. 1 started in 2020.
This study's enrollment of 161 is above the median of 60 across 151 interventional studies indexed under Liver Cirrhosis, Biliary.
Median enrollment 93 across the 6 interventional studies, 40 across the 4 observational. Of the 4 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Ipsen is the lead sponsor of 289 studies on the registry; 17 are open to participants now.
Of its 26 completed or terminated interventional studies of FDA-regulated products, 22 (85%) have results posted.
1 of the studies in Liver Cirrhosis, Biliary by Ipsen that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06730061Phase 3IpsenA Study of Elafibranor in Adult Japanese Participants With Primary Biliary Cholangitis (PBC) | 2026-12-17 |
Add it to your calendar (.ics) → With an account.
Among the 10 studies in Liver Cirrhosis, Biliary by Ipsen, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The participants of this study will have confirmed Primary Biliary Cholangitis (PBC) with inadequate response or intolerance to ursodeoxycholic acid (which is a medication used in the management and treatment of cholestatic liver disease).
PBC is a slowly progressive disease characterized by damage of the bile ducts in the liver, leading to a buildup of bile acids which causes further damage. The liver damage in PBC may lead to scarring (cirrhosis). PBC may also be associated with multiple symptoms. Many patients with PBC may require liver transplant or may die if the disease progresses and a liver transplant is not done.
The main aim of this study is to determine if elafibranor (the study drug) is better than placebo (a dummy treatment) at decreasing the levels of a specific blood test (alkaline phosphatase) that provides information about participant's disease. This study will also evaluate the safety of long-term treatment with elafibranor, as well as the impact on symptoms such as itchy skin (pruritus) and tiredness (fatigue).
This study has two main parts:
Part 1 will compare a daily dose of elafibranor to a daily dose of placebo and will last between a minimum of one year and a maximum of two years.
Part 2, all participants will receive elafibranor for a period of up to 5 years or until the total treatment duration (part 1 and part 2) reaches 6 years, whichever occurs first.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Study participants will take 1 tablet per day orally before breakfast with a glass of water each morning
Drug: Elafibranor 80mg
Study participants will take 1 tablet per day orally before breakfast with a glass of water each morning
Drug: Placebo
Study participants will take 1 tablet per day orally before breakfast with a glass of water each morning
Drug: Elafibranor 80mg
Elafibranor 80mg daily
Also known as: Iqirvo®
Placebo daily
Percentage of Participants With Response to Treatment Based on Cholestasis Response at Week 52
Cholestasis response was defined as alkaline phosphatase (ALP) \< 1.67 x upper limit of normal (ULN) and total bilirubin (TB) \<= ULN and ALP decrease from baseline \>= 15% at Week 52 and based on the composite strategy imputing non-response for participants who experienced intercurrent events (ICEs) (study treatment discontinuation or use of rescue therapy for PBC) prior to Week 52.
Time frame: At Week 52
Key Secondary Endpoint: Percentage of Participants With Response to Treatment Based on ALP Normalization at Week 52
Response to treatment based on normalization of ALP at Week 52 was defined as percentage of participants with ALP =\<1.0× ULN and based on the composite strategy imputing non-response for participants who experienced ICEs (study treatment discontinuation or use of rescue therapy for PBC) prior to Week 52.
Time frame: At Week 52
Key Secondary Endpoint: Change From Baseline in Pruritus Based on PBC Worst Itch Numeric Rating Scale (NRS) Score in Participants With Baseline PBC Worst Itch NRS Score ≥4 to Week 52
The PBC Worst Itch NRS is a simple, self-administered patient reported outcome (PRO) questionnaire that measures itch intensity. Participants rate intensity of their worst Itch on an 11-point scale ranging from 0 (no itch) to 10 (worst itch imaginable). Total score ranged from 0 (no itch) to 10 (worst itch imaginable). Higher scores indicated worse outcomes. Baseline was defined as the average of the daily PBC Worst itch scores on available data within 14 days prior the day of randomization. Post-baseline data was defined as the average of the daily PBC Worst itch scores on available data in 4-week period intervals (available data every 28 days after the day of first study drug intake).
Time frame: Baseline (up to 14 days pre-dose) and Week 52
Key Secondary Endpoint: Change From Baseline in Pruritus Based on PBC Worst Itch NRS Score in Participants With Baseline PBC Worst Itch NRS Score ≥4 to Week 24
The PBC Worst Itch NRS is a simple, self-administered PRO questionnaire that measures itch intensity. Participants rate intensity of their worst Itch on an 11-point scale ranging from 0 (no itch) to 10 (worst itch imaginable). Total score ranged from 0 (no itch) to 10 (worst itch imaginable). Higher scores indicated worse outcomes. Baseline was defined as the average of the daily PBC Worst itch scores on available data within 14 days prior the day of randomization. Post-baseline data was defined as the average of the daily PBC Worst itch scores on available data in 4-week period intervals (available data every 28 days after the day of first study drug intake).
Time frame: Baseline (up to 14 days pre-dose) and Week 24
Change From Baseline in ALP at Weeks 4, 13, 26, 39 and 52
Blood samples were collected at specified timepoints for assessment of ALP. Baseline was defined as the last non-missing central value on or before the first dose of the randomized study medication.
Time frame: Baseline (Day 1) and at Weeks 4, 13, 26, 39 and 52
Percentage of Participants With ALP Response From Baseline at Week 52
ALP response was defined as ALP decrease from baseline \>= 10%; ALP decrease from baseline \>= 20% and ALP decrease from baseline \>= 40% at Week 52 and based on the composite strategy imputing non-response for participants who experienced ICEs (study treatment discontinuation or use of rescue therapy for PBC) prior to Week 52. Baseline was defined as the last non-missing central value on or before the first dose of the randomized study medication.
Time frame: Baseline (Day 1) and at Week 52
Percentage of Participants With Response to Treatment According to ALP < 1.5x ULN, ALP Decrease From Baseline >= 40% and TB =<ULN at Week 52
Response to treatment was according to ALP \< 1.5x ULN, ALP decrease from baseline \>= 40% and TB =\<ULN at Week 52. It was based on the composite strategy imputing non-response for participants who experienced ICEs (study treatment discontinuation or use of rescue therapy for PBC) prior to Week 52. Baseline was defined as the last non-missing central value on or before the first dose of the randomized study medication.
Time frame: At Week 52
Percentage of Participants With Response to Treatment According to ALP < 3x ULN, Aspartate Aminotransferase (AST) < 2x ULN and TB =< 1 Milligrams Per Deciliter (mg/dL) (Paris I) at Week 52
Response to treatment was according to ALP \< 3x ULN, AST \< 2x ULN and TB =\< 1 mg/dL (Paris I) at Week 52. It was based on the composite strategy imputing non-response for participants who experienced ICEs (study treatment discontinuation or use of rescue therapy for PBC) prior to Week 52.
Time frame: At Week 52
Percentage of Participants With Response to Treatment According to ALP =< 1.5x ULN, AST =< 1.5x ULN and TB =< 1 mg/dL (Paris II) at Week 52
Response to treatment was according to ALP =\< 1.5x ULN, AST =\< 1.5x ULN and TB =\< 1 mg/dL (Paris II) at Week 52. It was based on the composite strategy imputing non-response for participants who experienced ICEs (study treatment discontinuation or use of rescue therapy for PBC) prior to Week 52.
Time frame: At Week 52
Percentage of Participants With Response to Treatment According to TB Decrease of 15% Change From Baseline at Week 52
Response to treatment was according to TB decrease of 15% change from baseline at Week 52. It was based on the composite strategy imputing non-response for participants who experienced ICEs (study treatment discontinuation or use of rescue therapy for PBC) prior to Week 52. Baseline was defined as the last non-missing central value on or before the first dose of the randomized study medication.
Time frame: At Week 52
Percentage of Participants With Response to Treatment According to Normalization of TB (TB =< ULN) and/or Albumin (ALB >= Lower Limit of Normal [LLN]) (Rotterdam) at Week 52
Response to treatment was according to TB (TB =\< ULN) and/or albumin (ALB \>= LLN) (Rotterdam) at week 52. Participant was considered as responder at Week 52 only if total bilirubin and albumin were normal. The endpoint was analyzed in participants with abnormal total bilirubin (TB \> ULN) or albumin (ALB \< LLN) at baseline. It was based on the composite strategy imputing non-response for participants who experienced ICEs (study treatment discontinuation or use of rescue therapy for PBC) prior to Week 52.
Time frame: At Week 52
Percentage of Participants With Response to Treatment According to TB ≤0.6 x ULN at Week 52
Response to treatment was according to TB ≤0.6 x ULN at Week 52. It was based on the composite strategy imputing non-response for participants who experienced ICEs (study treatment discontinuation or use of rescue therapy for PBC) prior to Week 52.
Time frame: At Week 52
Percentage of Participants With Response to Treatment According to ALP ≤1.67 x ULN and TB ≤1 mg/dL (Momah/ Lindor) at Week 52
Response to treatment was according to ALP ≤1.67 x ULN and TB ≤1 mg/dL (Momah/ Lindor) at Week 52. It was based on the composite strategy imputing non-response for participants who experienced ICEs (study treatment discontinuation or use of rescue therapy for PBC) prior to Week 52.
Time frame: At Week 52
Percentage of Participants With Response to Treatment According to no Worsening of TB at Week 52
Response to treatment was according to no worsening of TB, which was defined as level of TB \<ULN or no increase from baseline of more than 0.1 x ULN at Week 52. It was based on the composite strategy imputing non-response for participants who experienced ICEs (study treatment discontinuation or use of rescue therapy for PBC) prior to Week 52.
Time frame: At Week 52
Percentage of Participants With Response to Treatment According to Complete Biochemical Response at Week 52
Response to treatment according to complete biochemical response which was defined as \<= ULN values of ALP, TB, AST, ALT and ALB, and international normalized ratio (INR) at Week 52. It was based on the composite strategy imputing non-response for participants who experienced ICEs (study treatment discontinuation or use of rescue therapy for PBC) prior to Week 52.
Time frame: At Week 52
PBC 5-, 10- and 15-year Risk Scores Based on United Kingdom (UK)-PBC Score at Week 52
The UK-PBC risk score was defined by the mean percentage risk that a PBC participant treated with UDCA would develop liver failure requiring liver transplantation in 5, 10, and 15 years from diagnosis. It is calculated from the following equation at week 52 as follows: UK-PBC score = 0.0287854\*(alpEPxULN-1.722136304) - 0.0422873\*(\[{altastEP x ULN/10}\^-1\] - 8.675729006) + 1.4199 \* (LN(bilEPxULN /10)+2.709607778) - 1.960303\*(alb x LLN -1.17673001)-0.4161954\*(plt x LLN -1.873564875). The survival S(t) for any given participants was then calculated by S(t) = S0(t) exp(UK-PBC score). Here, alpEP x ULN=ALP /Upper Level Normal ALP at the timepoint, altastEPxULN=(ALT, AST or TA) /upper level normal of the value at the timepoint, bilEP x ULN=bilirubin /upper level normal bilirubin at the timepoint, alb x LLN=alb /alb lower level normal at baseline and plt x LLN=plt/plt lower level normal at baseline. Lower UK-PBC score predicts lower risk and better prognosis.
Time frame: At Week 52
Global PBC Study Group (GLOBE) Score at Week 52
The GLOBE score was a validated risk assessment tool providing an estimate of transplant-free survival for participants with PBC. It was developed by the Global PBC Study Group using Cox regression model on over 4,000 participants with PBC. It is calculated from the following equation at week 52 as follows: GLOBE score = 0.044378 \* age at start of ursodeoxycholic acid (UDCA) therapy + 0.93982 \* LN (TB x ULN) + 0.335648 \* LN (ALP x ULN) - 2.266708 \* ALB x LLN - 0.002581 \* platelet count per 10\^9/L) + 1.216865; where TB x ULN = bilirubin/ULN at the timepoint, ALP x ULN = ALP/ULN at the timepoint, ALB x LLN = ALB/LLN at the timepoint, platelet count per 10\^9/L = platelet count per 10\^9/L at the timepoint. The Lower GLOBE PBC score predicts lower risk and better prognosis.
Time frame: At Week 52
Change From Baseline in Hepatobiliary Injury and Liver Function as Assessed by AST, ALT, Gamma-glutamyl Transferase (GGT), 5 Prime Nucleotidase (5'-NT), and Fractionated ALP (Hepatic) (H1 and H2) at Week 52
Hepatobiliary injury and liver function were assessed as measured by AST, ALT, GGT, 5'-NT, and fractionated ALP (hepatic) (H1 and H2). Baseline was defined as the last non-missing central value on or before the first dose of the randomized study medication.
Time frame: Baseline (Day 1) and at Week 52
Change From Baseline in Hepatobiliary Injury and Liver Function as Measured by Total and Conjugated Bilirubin at Week 52
Hepatobiliary injury and liver function were assessed as measured by total and conjugated bilirubin. Baseline was defined as the last non-missing central value on or before the first dose of the randomized study medication.
Time frame: Baseline (Day 1) and at Week 52
Change From Baseline in Hepatobiliary Injury and Liver Function as Measured by Albumin at Week 52
Hepatobiliary injury and liver function were assessed as measured by albumin. Baseline was defined as the last non-missing central value on or before the first dose of the randomized study medication.
Time frame: Baseline (Day 1) and at Week 52
Change From Baseline in Hepatobiliary Injury and Liver Function as Measured by INR at Week 52
Hepatobiliary injury and liver function were assessed as measured by INR. Baseline was defined as the last non-missing central value on or before the first dose of the randomized study medication.
Time frame: Baseline (Day 1) and at Week 52
Change From Baseline in Biomarkers of Inflammation as Measured by High-sensitivity C-reactive Protein (hsCRP) at Week 52
Biomarkers of inflammation were assessed as measured by hsCRP. Baseline was defined as the last non-missing central value on or before the first dose of the randomized study medication.
Time frame: Baseline (Day 1) and at Week 52
Change From Baseline in Biomarkers of Inflammation as Measured by Fibrinogen and Haptoglobin at Week 52
Biomarkers of inflammation were assessed as measured by fibrinogen and haptoglobin. Baseline was defined as the last non-missing central value on or before the first dose of the randomized study medication.
Time frame: Baseline (Day 1) and at Week 52
Change From Baseline in Biomarkers of Inflammation as Measured by Tumor Necrosis Factor Alpha at Week 52
Biomarkers of inflammation were assessed as measured by TNF-alpha. Baseline was defined as the last non-missing central value on or before the first dose of the randomized study medication.
Time frame: Baseline (Day 1) and at Week 52
Change From Baseline in Immune Response as Measured by Immunoglobulin (Ig)G and IgM at Week 52
Immune response was assessed as measured by IgG and IgM. Baseline was defined as the last non-missing central value on or before the first dose of the randomized study medication.
Time frame: Baseline (Day 1) and at Week 52
Change From Baseline in Biomarkers and Non-invasive Measures of Hepatic Fibrosis as Measured by Enhanced Liver Fibrosis (ELF) and Plasminogen Activator Inhibitor-1 (PAI-1) at Week 52
Biomarkers and non-invasive measures of hepatic fibrosis were assessed as measured by ELF: hyaluronic acid \[HA\], type 2 procollagen peptide \[PIINP\], tissue inhibitor of metalloproteinases-1\[TIMP-1\]) and PAI-1. Baseline was defined as the last non-missing central value on or before the first dose of the randomized study medication.
Time frame: Baseline (Day 1) and at Week 52
Change From Baseline in Biomarkers and Non-invasive Measures of Hepatic Fibrosis as Measured by Cytokeratin-18 (CK-18) at Week 52
Biomarkers and non-invasive measures of hepatic fibrosis were assessed as measured by CK-18 (M30 and M65). Baseline was defined as the last non-missing central value on or before the first dose of the randomized study medication.
Time frame: Baseline (Day 1) and at Week 52
Change From Baseline in Biomarkers and Non-invasive Measures of Hepatic Fibrosis as Measured by Transforming Growth Factor Beta (TGF-beta) at Week 52
Biomarkers and non-invasive measures of hepatic fibrosis were assessed as measured by TGF-beta. Baseline was defined as the last non-missing central value on or before the first dose of the randomized study medication.
Time frame: Baseline (Day 1) and at Week 52
Change From Baseline in Liver Stiffness Measured by Transient Elastography (TE) at Week 52
FibroScan® TE device (Echosens, Paris, France) is a non-invasive technique used to measure liver stiffness, which correlated with fibrosis. Baseline was defined as the last non-missing value on or before the first dose of the randomized study medication.
Time frame: Baseline (Day 1) and at Week 52
Change From Baseline in Lipid Parameters at Week 52
Blood samples were collected at specified timepoints for assessment of total cholesterol, low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol, very low-density lipoprotein (VLDL) cholesterol and triglycerides (TG). Baseline was defined as the last non-missing central value on or before the first dose of the randomized study medication.
Time frame: Baseline (Day 1) and at Week 52
Change From Baseline in Fasting Plasma Glucose (FPG) at Week 52
Blood samples were collected at specified timepoints for assessment of FPG. Baseline was defined as the last non-missing central value on or before the first dose of the randomized study medication.
Time frame: Baseline (Day 1) and at Week 52
Change From Baseline in Bile Acids and Biomarkers of Bile Acid Synthesis at Week 52
Blood samples were collected at specified timepoints for assessment bile acids and biomarkers of bile acid synthesis. Baseline was defined as the last non-missing central value on or before the first dose of the randomized study medication.
Time frame: Baseline (Day 1) and at Week 52
Change From Baseline at Week 52 in Bile Acids and Biomarkers of Bile Acid Synthesis as Measured by 7 Alpha-hydroxy-4-cholesten-3-one (C4) at Week 52
Blood samples were collected at specified timepoints for assessment of bile acids and biomarkers of bile acid synthesis as measured by C4. Baseline was defined as the last non-missing central value on or before the first dose of the randomized study medication.
Time frame: Baseline (Day 1) and at Week 52
Change From Baseline in Bile Acids and Biomarkers of Bile Acid Synthesis as Measured Fibroblast Growth Factor 19 at Week 52
Blood samples were collected at specified timepoints for assessment bile acids and biomarkers of bile acid synthesis as measured by Fibroblast Growth Factor 19. Baseline was defined as the last non-missing central value on or before the first dose of the randomized study medication.
Time frame: Baseline (Day 1) and at Week 52
Percentage of Participants With Response in PBC Worst Itch NRS Score at Weeks 24 and 52
The PBC Worst Itch NRS is a simple, self-administered PRO questionnaire that measures itch intensity. Participants rate intensity of their worst Itch on an 11-point scale ranging from 0 (no itch) to 10 (worst itch imaginable). Total score ranged from 0 (no itch) to 10 (worst itch imaginable). Higher scores indicated worse outcomes. Response to PBC Worst Itch NRS was according to clinically meaningful change at least 30% reduction; one point, two points or three points decrease in score from baseline in participants with a baseline NRS score ≥4. Baseline was defined as the average of the daily PBC Worst itch scores on available data within 14 days prior the day of randomization. Post-baseline data was defined as the average of the daily PBC Worst itch scores on available data in 4-week period intervals (available data every 28 days after the day of first study drug intake).
Time frame: Baseline (up to 14 days pre-dose) and at Week 24 and Week 52
Percentage of Participants With no Worsening of Pruritus as Measured by the PBC Worst Itch NRS Score at Weeks 24 and 52
The PBC Worst Itch NRS is a simple, self-administered PRO questionnaire that measures itch intensity. Participants rate intensity of their worst Itch on an 11-point scale ranging from 0 (no itch) to 10 (worst itch imaginable). Total score ranged from 0 (no itch) to 10 (worst itch imaginable). Higher scores indicated worse outcomes. Baseline was defined as the average of the daily PBC Worst itch scores on available data within 14 days prior the day of randomization. Post-baseline data was defined as the average of the daily PBC Worst itch scores on available data in 4-week period intervals (available data every 28 days after the day of first study drug intake). A worsening of Pruritus was defined by a positive change from baseline in PBC Worst Itch NRS score greater than 2 at week 24 and 52.
Time frame: Baseline (up to 14 days pre-dose) and at Week 24 and Week 54
Change From Baseline in 5-D Itch at Week 52
The 5-D Itch scale is a questionnaire that has been validated in several different diseases. It assesses symptoms in terms of 5 domains: duration: score range 1 (less than 6 hours) to 5 (all day); degree: score range 1 (not present) to 5 (unbearable); duration: score range 1 (less than 6 hours) and 5 (all day); direction: score range 1(completely resolved) and 5 (getting worse); disability: score range 1 (never affects or not applicable) and 5 (delays falling asleep and frequently wakes up at night or always affects this activity) and distribution: where the question was to mark where itching is present in body parts over the last two weeks. Participants rated their symptoms over preceding 2-week period on a 1 to 5 scale, with 5 being the most affected. The 5-D Itch total score ranged between 5 (no pruritus) and 25 (most severe pruritus). Higher scores indicated worse outcomes. Baseline= last non-missing value on or before the first dose of the randomized study medication.
Time frame: Baseline (Day 1) and at Week 52
Change From Baseline in Patient-Reported Outcomes Measurement Information System (PROMIS) Fatigue Short Form 7a at Week 52
The PROMIS Fatigue Short Form 7a consists of seven items that measure both the experience of fatigue and the interference of fatigue on daily activities over the past week. Participants completed the PROMIS Fatigue Short Form 7a and answered following questions on a scale from 1 (never) to 5 (always) : "How often did you feel tired"; "How often did you experience extreme exhaustion"; "How often did you run out of energy"; "How often did your fatigue limit you at work"; "How often were you too tired to think clearly"; "How often were you too tired to take a bath or shower" and 'How often did you have enough energy to exercise strenuously". T-score values include mean of 50 and standard deviation of 10. The PROMIS Fatigue T-score ranged from 29.4 (best) to 83.2 (worst). Higher scores indicated worse outcomes. Baseline was defined as the last non-missing value on or before the first dose of the randomized study medication.
Time frame: Baseline (Day 1) and at Week 52
Change From Baseline in Epworth Sleepiness Scale (ESS) at Week 52
The ESS is a short, self-administered questionnaire that consists of 8 questions asking to rate how likely it is to fall asleep in everyday situations (each question can be scored from 0 to 3 points; '0' indicates no chance of dozing and '3' indicates high chance of dozing). It provides a total score which has been shown to relate to the participant's level of daytime sleepiness (total score range 0 \[no sleepiness\] to 24 points \[significant sleepiness\]). The total score is the sum of all item scores and ranged from 0 (best) to 24 (worst). Higher scores indicated more chances of sleepiness. Participants were asked to complete the ESS with regard to the level of sleepiness they experienced over approximately the past 7 days. Baseline was defined as the last non-missing value on or before the first dose of the randomized study medication.
Time frame: Baseline (Day 1) and at Week 52
Change From Baseline in PBC-40 at Week 52
PBC-40 assess symptoms across 6 domains:symptoms,itch,fatigue,cognitive,emotional and social. Participants responded on verbal response scale,depending on section options range from 'never'/'not at all'/'strongly disagree' to 'always'/'very much'/'strongly agree'.5 items (3/3 in itch domain and 2/10 in social domain)also included a 'does not apply' option.Domains:Symptoms(7 questions)score range 7-35,Itch(3 questions)score range 3-15,Fatigue(11 questions)score range 11-55,Cognitive(6 questions)score range 6-30,Emotional(3 questions)score range 3-15,Social(10 questions)score range 10-50.Score for each domain was provided(total score was not calculated),with each verbal response scale correlating to score of 1-5 per item(0-5 on items with a 'does not apply' option);5=most affected.Individual item scores are summed to give total domain score.Higher scores=worse outcomes.PBC-40 had 4-week recall period.Baseline=last non-missing value on or before first dose of randomized study medication.
Time frame: Baseline (Day 1) and at Week 52
Change From Baseline in Health Utility as Measured by the European Quality of Life 5 Dimensions 5 Level Version (EQ-5D-5L) at Week 52
The EQ-5D-5L is a 6-item, standardized questionnaire that assesses mobility, self-care, usual activities, pain/discomfort, anxiety/depression, and overall health state. The visual analog scale (VAS) of EQ-5D-5L questionnaire is numbered from 0 (worst) to 100 (best). Higher scores indicated better outcomes. Baseline was defined as the last non-missing value on or before the first dose of the randomized study medication.
Time frame: Baseline (Day 1) and at Week 52
Change From Baseline in T-Scores for Bone Mineral Density Assessed by Dual-energy X-ray Absorptiometry (DEXA) Scanning at Week 52
DEXA scanning (hip and lumbar) was performed in participants to assess bone mineral density (femoral neck, lumbar and total hip). T-scores were calculated based on actual measured bone density value. The T-score compared a participant's bone density against that of a healthy 30-year-old adult. T-scores were used to determine primary osteoporosis, which exists on its own without any other cause and were divided into 3 categories: low risk, medium risk, and high risk (osteoporosis). T-scores measure the number of minerals in a participant's bone. A participant's level of bone loss was compared to that of a typical, healthy 30-year-old adult. A score ≥-1.0 indicates low risk, medium risk is a score between-2.5 and -1.0, and a high risk/osteoporosis is a score ≤-2.5. A positive change in T-score indicates an improvement in bone mineral density. Baseline was defined as the last non-missing central value on or before the first dose of the randomized study medication.
Time frame: Baseline (Day 1) and at Week 52
Change From Baseline in Serum Markers of Bone Turnover Carboxy Terminal Crosslinked Telopeptides of Type 1 Collagen [CTX] at Week 52
Blood samples were collected at specified timepoints for assessment of serum markers of bone turnover, CTX. Baseline was defined as the last non-missing central value on or before the first dose of the randomized study medication.
Time frame: Baseline (Day 1) and at Week 52
Change From Baseline in Serum Markers of Bone Turnover Type 1 Procollagen Peptide [P1NP]) at Week 52
Blood samples were collected at specified timepoints for assessment of serum markers of bone turnover, P1NP. Baseline was defined as the last non-missing central value on or before the first dose of the randomized study medication.
Time frame: Baseline (Day 1) and at Week 52
Percentage of Participants With Onset of Clinical Outcomes
Onset of clinical outcomes were described as a composite endpoint composed of the following: model for end stage liver disease sodium (MELD-Na) \>14 for participants with baseline MELD-Na \<12; liver transplant; uncontrolled ascites requiring treatment; hospitalization for new onset or recurrence of any including, variceal bleed, hepatic encephalopathy defined as West-Haven score of 2 or more and spontaneous bacterial peritonitis; and death.
Time frame: From Day 1 up to Week 52
Number of Participants With Treatment-emergent Adverse Events (TEAEs), Treatment-emergent Serious Adverse Events (TESAEs) and Adverse Events of Special Interest (AESIs)
An AE was any untoward medical occurrence in a participant or clinical investigation participant who was administered an investigational product, and which does not necessarily have a causal relationship with treatment. A TEAE was defined as any AE with onset during TEAE assessment period, or any event started prior to first dose of treatment and worsened or became serious during the TEAE assessment period. An SAE was any AE that resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital abnormality/birth defect. An AESI was an AE that might not be serious but was of special importance to a particular treatment or class.
Time frame: TEAEs were collected from the start of study treatment administration (Day 1) up to DCO date of 01 June 2023, approximately 980 days.
Plasma Concentrations of Elafibranor and GFT1007
Blood samples were collected at specified timepoints to evaluate plasma concentration of Elafibranor and its metabolite GFT1007.
Time frame: Week 4: pre-dose, 0.5 hour, 1.5 hours, between 2-3 hours, 4 hours and 6 hours post-dose
This Phase III, double-blind (DB), placebo-controlled study followed by an open-label long-term extension (LTE) was conducted in participants with primary biliary cholangitis (PBC) at 82 sites in 14 countries (Argentina, Belgium, Brazil, Canada, Chile, France, Germany, Italy, South Africa, Spain, Switzerland, Turkey, United Kingdom, and United States). First participant was recruited on 24 September 2020 and data cut-off (DCO) date was 01 June 2023.
| Milestone | Elafibranor 80 mg | Placebo |
|---|---|---|
| Started | 108 | 53 |
| Completed | 94 | 46 |
| Not completed | 14 | 7 |
| Withdrew: Withdrawal by subject | 6 | 3 |
| Withdrew: Adverse event | 4 | 1 |
| Withdrew: Physician decision | 2 | 2 |
| Withdrew: Death | 2 | 0 |
| Withdrew: Other | 0 | 1 |
Cholestasis response was defined as alkaline phosphatase (ALP) \< 1.67 x upper limit of normal (ULN) and total bilirubin (TB) \<= ULN and ALP decrease from baseline \>= 15% at Week 52 and based on the composite strategy imputing non-response for participants who experienced intercurrent events (ICEs) (study treatment discontinuation or use of rescue therapy for PBC) prior to Week 52.
| Percentage of participants | Elafibranor 80 mg | Placebo |
|---|---|---|
| Percentage of Participants With Response to Treatment Based on Cholestasis Response at Week 52 | 50.9 (41.6 to 60.2) | 3.8 (1.0 to 12.8) |
Response to treatment based on normalization of ALP at Week 52 was defined as percentage of participants with ALP =\<1.0× ULN and based on the composite strategy imputing non-response for participants who experienced ICEs (study treatment discontinuation or use of rescue therapy for PBC) prior to Week 52.
| Percentage of participants | Elafibranor 80 mg | Placebo |
|---|---|---|
| Key Secondary Endpoint: Percentage of Participants With Response to Treatment Based on ALP Normalization at Week 52 | 14.8 (9.3 to 22.7) | 0 (0.0 to 6.8) |
The PBC Worst Itch NRS is a simple, self-administered patient reported outcome (PRO) questionnaire that measures itch intensity. Participants rate intensity of their worst Itch on an 11-point scale ranging from 0 (no itch) to 10 (worst itch imaginable). Total score ranged from 0 (no itch) to 10 (worst itch imaginable). Higher scores indicated worse outcomes. Baseline was defined as the average of the daily PBC Worst itch scores on available data within 14 days prior the day of randomization. Post-baseline data was defined as the average of the daily PBC Worst itch scores on available data in 4-week period intervals (available data every 28 days after the day of first study drug intake).
| Scores on a scale | Elafibranor 80 mg | Placebo |
|---|---|---|
| Key Secondary Endpoint: Change From Baseline in Pruritus Based on PBC Worst Itch Numeric Rating Scale (NRS) Score in Participants With Baseline PBC Worst Itch NRS Score ≥4 to Week 52 | -1.930 (-2.602 to -1.258) | -1.146 (-2.143 to -0.150) |
The PBC Worst Itch NRS is a simple, self-administered PRO questionnaire that measures itch intensity. Participants rate intensity of their worst Itch on an 11-point scale ranging from 0 (no itch) to 10 (worst itch imaginable). Total score ranged from 0 (no itch) to 10 (worst itch imaginable). Higher scores indicated worse outcomes. Baseline was defined as the average of the daily PBC Worst itch scores on available data within 14 days prior the day of randomization. Post-baseline data was defined as the average of the daily PBC Worst itch scores on available data in 4-week period intervals (available data every 28 days after the day of first study drug intake).
| Scores on a scale | Elafibranor 80 mg | Placebo |
|---|---|---|
| Key Secondary Endpoint: Change From Baseline in Pruritus Based on PBC Worst Itch NRS Score in Participants With Baseline PBC Worst Itch NRS Score ≥4 to Week 24 | -1.598 (-2.246 to -0.951) | -1.255 (-2.201 to -0.309) |
Blood samples were collected at specified timepoints for assessment of ALP. Baseline was defined as the last non-missing central value on or before the first dose of the randomized study medication.
| Units per Liter (U/L) | Elafibranor 80 mg | Placebo |
|---|---|---|
| Week 4 | -116.4 ± 63.1 | -14.3 ± 92.6 |
| Week 13 | -131.8 ± 74.6 | -19.1 ± 78.3 |
| Week 26 | -126.2 ± 85.5 | -6.0 ± 75.6 |
| Week 39 | -134.7 ± 89.8 | -20.0 ± 90.1 |
| Week 52 | -117.7 ± 96.5 | -8.8 ± 91.2 |
ALP response was defined as ALP decrease from baseline \>= 10%; ALP decrease from baseline \>= 20% and ALP decrease from baseline \>= 40% at Week 52 and based on the composite strategy imputing non-response for participants who experienced ICEs (study treatment discontinuation or use of rescue therapy for PBC) prior to Week 52. Baseline was defined as the last non-missing central value on or before the first dose of the randomized study medication.
| Percentage of participants | Elafibranor 80 mg | Placebo |
|---|---|---|
| ALP response >= 10% decrease from baseline | 75.5 | 22.6 |
| ALP response >= 20% decrease from baseline | 69.8 | 5.7 |
| ALP response >= 40% decrease from baseline | 54.7 | 0.0 |
Response to treatment was according to ALP \< 1.5x ULN, ALP decrease from baseline \>= 40% and TB =\<ULN at Week 52. It was based on the composite strategy imputing non-response for participants who experienced ICEs (study treatment discontinuation or use of rescue therapy for PBC) prior to Week 52. Baseline was defined as the last non-missing central value on or before the first dose of the randomized study medication.
| Percentage of participants | Elafibranor 80 mg | Placebo |
|---|---|---|
| Percentage of Participants With Response to Treatment According to ALP < 1.5x ULN, ALP Decrease From Baseline >= 40% and TB =<ULN at Week 52 | 37.7 | 0.0 |
Response to treatment was according to ALP \< 3x ULN, AST \< 2x ULN and TB =\< 1 mg/dL (Paris I) at Week 52. It was based on the composite strategy imputing non-response for participants who experienced ICEs (study treatment discontinuation or use of rescue therapy for PBC) prior to Week 52.
| Percentage of participants | Elafibranor 80 mg | Placebo |
|---|---|---|
| Percentage of Participants With Response to Treatment According to ALP < 3x ULN, Aspartate Aminotransferase (AST) < 2x ULN and TB =< 1 Milligrams Per Deciliter (mg/dL) (Paris I) at Week 52 | 68.9 | 47.2 |
Response to treatment was according to ALP =\< 1.5x ULN, AST =\< 1.5x ULN and TB =\< 1 mg/dL (Paris II) at Week 52. It was based on the composite strategy imputing non-response for participants who experienced ICEs (study treatment discontinuation or use of rescue therapy for PBC) prior to Week 52.
| Percentage of participants | Elafibranor 80 mg | Placebo |
|---|---|---|
| Percentage of Participants With Response to Treatment According to ALP =< 1.5x ULN, AST =< 1.5x ULN and TB =< 1 mg/dL (Paris II) at Week 52 | 43.0 | 5.7 |
Response to treatment was according to TB decrease of 15% change from baseline at Week 52. It was based on the composite strategy imputing non-response for participants who experienced ICEs (study treatment discontinuation or use of rescue therapy for PBC) prior to Week 52. Baseline was defined as the last non-missing central value on or before the first dose of the randomized study medication.
| Percentage of participants | Elafibranor 80 mg | Placebo |
|---|---|---|
| Percentage of Participants With Response to Treatment According to TB Decrease of 15% Change From Baseline at Week 52 | 31.4 | 22.6 |
Response to treatment was according to TB (TB =\< ULN) and/or albumin (ALB \>= LLN) (Rotterdam) at week 52. Participant was considered as responder at Week 52 only if total bilirubin and albumin were normal. The endpoint was analyzed in participants with abnormal total bilirubin (TB \> ULN) or albumin (ALB \< LLN) at baseline. It was based on the composite strategy imputing non-response for participants who experienced ICEs (study treatment discontinuation or use of rescue therapy for PBC) prior to Week 52.
| Percentage of participants | Elafibranor 80 mg | Placebo |
|---|---|---|
| TB (TB =< ULN) | 25.0 | 50.0 |
Response to treatment was according to TB ≤0.6 x ULN at Week 52. It was based on the composite strategy imputing non-response for participants who experienced ICEs (study treatment discontinuation or use of rescue therapy for PBC) prior to Week 52.
| Percentage of participants | Elafibranor 80 mg | Placebo |
|---|---|---|
| Percentage of Participants With Response to Treatment According to TB ≤0.6 x ULN at Week 52 | 74.3 | 77.4 |
Response to treatment was according to ALP ≤1.67 x ULN and TB ≤1 mg/dL (Momah/ Lindor) at Week 52. It was based on the composite strategy imputing non-response for participants who experienced ICEs (study treatment discontinuation or use of rescue therapy for PBC) prior to Week 52.
| Percentage of participants | Elafibranor 80 mg | Placebo |
|---|---|---|
| Percentage of Participants With Response to Treatment According to ALP ≤1.67 x ULN and TB ≤1 mg/dL (Momah/ Lindor) at Week 52 | 51.9 | 9.4 |
Response to treatment was according to no worsening of TB, which was defined as level of TB \<ULN or no increase from baseline of more than 0.1 x ULN at Week 52. It was based on the composite strategy imputing non-response for participants who experienced ICEs (study treatment discontinuation or use of rescue therapy for PBC) prior to Week 52.
| Percentage of participants | Elafibranor 80 mg | Placebo |
|---|---|---|
| Percentage of Participants With Response to Treatment According to no Worsening of TB at Week 52 | 85.7 | 83.0 |
Response to treatment according to complete biochemical response which was defined as \<= ULN values of ALP, TB, AST, ALT and ALB, and international normalized ratio (INR) at Week 52. It was based on the composite strategy imputing non-response for participants who experienced ICEs (study treatment discontinuation or use of rescue therapy for PBC) prior to Week 52.
| Percentage of participants | Elafibranor 80 mg | Placebo |
|---|---|---|
| Percentage of Participants With Response to Treatment According to Complete Biochemical Response at Week 52 | 9.3 | 0.0 |
The UK-PBC risk score was defined by the mean percentage risk that a PBC participant treated with UDCA would develop liver failure requiring liver transplantation in 5, 10, and 15 years from diagnosis. It is calculated from the following equation at week 52 as follows: UK-PBC score = 0.0287854\*(alpEPxULN-1.722136304) - 0.0422873\*(\[{altastEP x ULN/10}\^-1\] - 8.675729006) + 1.4199 \* (LN(bilEPxULN /10)+2.709607778) - 1.960303\*(alb x LLN -1.17673001)-0.4161954\*(plt x LLN -1.873564875). The survival S(t) for any given participants was then calculated by S(t) = S0(t) exp(UK-PBC score). Here, alpEP x ULN=ALP /Upper Level Normal ALP at the timepoint, altastEPxULN=(ALT, AST or TA) /upper level normal of the value at the timepoint, bilEP x ULN=bilirubin /upper level normal bilirubin at the timepoint, alb x LLN=alb /alb lower level normal at baseline and plt x LLN=plt/plt lower level normal at baseline. Lower UK-PBC score predicts lower risk and better prognosis.
| Scores on a scale | Elafibranor 80 mg | Placebo |
|---|---|---|
| UK PBC 5-year risk score | 0.0102 ± 0.0126 | 0.0146 ± 0.0264 |
| UK PBC 10-year risk score | 0.0330 ± 0.0393 | 0.0454 ± 0.0731 |
| UK PBC 15-year risk score | 0.0593 ± 0.0670 | 0.0786 ± 0.1109 |
The GLOBE score was a validated risk assessment tool providing an estimate of transplant-free survival for participants with PBC. It was developed by the Global PBC Study Group using Cox regression model on over 4,000 participants with PBC. It is calculated from the following equation at week 52 as follows: GLOBE score = 0.044378 \* age at start of ursodeoxycholic acid (UDCA) therapy + 0.93982 \* LN (TB x ULN) + 0.335648 \* LN (ALP x ULN) - 2.266708 \* ALB x LLN - 0.002581 \* platelet count per 10\^9/L) + 1.216865; where TB x ULN = bilirubin/ULN at the timepoint, ALP x ULN = ALP/ULN at the timepoint, ALB x LLN = ALB/LLN at the timepoint, platelet count per 10\^9/L = platelet count per 10\^9/L at the timepoint. The Lower GLOBE PBC score predicts lower risk and better prognosis.
| Scores on a scale | Elafibranor 80 mg | Placebo |
|---|---|---|
| Global PBC Study Group (GLOBE) Score at Week 52 | -1.03 ± 0.70 | -0.62 ± 0.83 |
Hepatobiliary injury and liver function were assessed as measured by AST, ALT, GGT, 5'-NT, and fractionated ALP (hepatic) (H1 and H2). Baseline was defined as the last non-missing central value on or before the first dose of the randomized study medication.
| U/L | Elafibranor 80 mg | Placebo |
|---|---|---|
| AST | -2.5 ± 17.8 | -4.3 ± 24.3 |
| ALT | -9.7 ± 22.1 | -6.3 ± 26.3 |
| GGT | -44.0 ± 95.6 | -17.3 ± 112.7 |
| 5'-NT | -3.63 ± 5.40 | -2.09 ± 10.52 |
| Hepatic ALP H1 | -107.68 ± 77.17 | -32.20 ± 71.42 |
| Hepatic ALP H2 | -11.76 ± 14.67 | -5.20 ± 54.83 |
Hepatobiliary injury and liver function were assessed as measured by total and conjugated bilirubin. Baseline was defined as the last non-missing central value on or before the first dose of the randomized study medication.
| Micromoles per liter (μmol/L) | Elafibranor 80 mg | Placebo |
|---|---|---|
| Total Bilirubin | -0.67 ± 3.18 | 0.87 ± 4.29 |
| Conjugated bilirubin | -0.09 ± 1.98 | 0.61 ± 2.41 |
Hepatobiliary injury and liver function were assessed as measured by albumin. Baseline was defined as the last non-missing central value on or before the first dose of the randomized study medication.
| Grams per liter (g/L) | Elafibranor 80 mg | Placebo |
|---|---|---|
| Change From Baseline in Hepatobiliary Injury and Liver Function as Measured by Albumin at Week 52 | 1.0 ± 2.8 | -1.2 ± 2.7 |
Hepatobiliary injury and liver function were assessed as measured by INR. Baseline was defined as the last non-missing central value on or before the first dose of the randomized study medication.
| Ratio | Elafibranor 80 mg | Placebo |
|---|---|---|
| Change From Baseline in Hepatobiliary Injury and Liver Function as Measured by INR at Week 52 | 0.028 ± 0.148 | 0.035 ± 0.131 |
Biomarkers of inflammation were assessed as measured by hsCRP. Baseline was defined as the last non-missing central value on or before the first dose of the randomized study medication.
| mg/L | Elafibranor 80 mg | Placebo |
|---|---|---|
| Change From Baseline in Biomarkers of Inflammation as Measured by High-sensitivity C-reactive Protein (hsCRP) at Week 52 | -1.38 ± 6.53 | 0.22 ± 2.64 |
Biomarkers of inflammation were assessed as measured by fibrinogen and haptoglobin. Baseline was defined as the last non-missing central value on or before the first dose of the randomized study medication.
| g/L | Elafibranor 80 mg | Placebo |
|---|---|---|
| Fibrinogen | -1.002 ± 1.303 | -0.776 ± 1.265 |
| Haptoglobin | -0.185 ± 0.407 | 0.023 ± 0.302 |
Biomarkers of inflammation were assessed as measured by TNF-alpha. Baseline was defined as the last non-missing central value on or before the first dose of the randomized study medication.
| Picograms per milliliter (pg/mL) | Elafibranor 80 mg | Placebo |
|---|---|---|
| Change From Baseline in Biomarkers of Inflammation as Measured by Tumor Necrosis Factor Alpha at Week 52 | -3.346 ± 15.442 | -0.224 ± 0.921 |
Immune response was assessed as measured by IgG and IgM. Baseline was defined as the last non-missing central value on or before the first dose of the randomized study medication.
| g/L | Elafibranor 80 mg | Placebo |
|---|---|---|
| IgG | -0.423 ± 1.591 | 0.298 ± 1.159 |
| IgM | -0.606 ± 0.907 | 0.017 ± 0.762 |
Biomarkers and non-invasive measures of hepatic fibrosis were assessed as measured by ELF: hyaluronic acid \[HA\], type 2 procollagen peptide \[PIINP\], tissue inhibitor of metalloproteinases-1\[TIMP-1\]) and PAI-1. Baseline was defined as the last non-missing central value on or before the first dose of the randomized study medication.
| Micrograms per liter (mcg/L) | Elafibranor 80 mg | Placebo |
|---|---|---|
| HA | 7.93 ± 80.35 | 16.36 ± 48.60 |
| PIINP | -2.79 ± 32.55 | -5.60 ± 20.03 |
| TIMP-1 | -3.03 ± 51.06 | 23.26 ± 65.03 |
| PAI-1 | 0.053 ± 3.032 | 0.785 ± 7.028 |
Biomarkers and non-invasive measures of hepatic fibrosis were assessed as measured by CK-18 (M30 and M65). Baseline was defined as the last non-missing central value on or before the first dose of the randomized study medication.
| Picomoles per liter (pmol/L) | Elafibranor 80 mg | Placebo |
|---|---|---|
| CK-18 M30 | -70.71 ± 444.31 | -5.39 ± 334.22 |
| CK-18 M65 | -50.02 ± 246.28 | -83.73 ± 481.30 |
Biomarkers and non-invasive measures of hepatic fibrosis were assessed as measured by TGF-beta. Baseline was defined as the last non-missing central value on or before the first dose of the randomized study medication.
| pg/mL | Elafibranor 80 mg | Placebo |
|---|---|---|
| Change From Baseline in Biomarkers and Non-invasive Measures of Hepatic Fibrosis as Measured by Transforming Growth Factor Beta (TGF-beta) at Week 52 | 713.074 ± 6553.956 | -6172.360 ± 3279.127 |
FibroScan® TE device (Echosens, Paris, France) is a non-invasive technique used to measure liver stiffness, which correlated with fibrosis. Baseline was defined as the last non-missing value on or before the first dose of the randomized study medication.
| Kilopascal (kPa) | Elafibranor 80 mg | Placebo |
|---|---|---|
| Change From Baseline in Liver Stiffness Measured by Transient Elastography (TE) at Week 52 | -0.16 ± 3.70 | 0.35 ± 6.39 |
Blood samples were collected at specified timepoints for assessment of total cholesterol, low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol, very low-density lipoprotein (VLDL) cholesterol and triglycerides (TG). Baseline was defined as the last non-missing central value on or before the first dose of the randomized study medication.
| Millimoles per liter (mmol/L) | Elafibranor 80 mg | Placebo |
|---|---|---|
| Total cholesterol | -0.532 ± 0.910 | -0.318 ± 1.144 |
| LDL cholesterol | -0.428 ± 0.730 | -0.274 ± 1.086 |
| HDL cholesterol | 0.011 ± 0.364 | -0.056 ± 0.399 |
| VLDL cholesterol | -0.118 ± 0.159 | 0.015 ± 0.156 |
| TG | -0.268 ± 0.370 | 0.031 ± 0.343 |
Blood samples were collected at specified timepoints for assessment of FPG. Baseline was defined as the last non-missing central value on or before the first dose of the randomized study medication.
| mmol/L | Elafibranor 80 mg | Placebo |
|---|---|---|
| Change From Baseline in Fasting Plasma Glucose (FPG) at Week 52 | -0.267 ± 0.861 | 0.086 ± 0.381 |
Blood samples were collected at specified timepoints for assessment bile acids and biomarkers of bile acid synthesis. Baseline was defined as the last non-missing central value on or before the first dose of the randomized study medication.
| µmol/L | Elafibranor 80 mg | Placebo |
|---|---|---|
| Chenodeoxycholic acid | 0.177 ± 0.807 | 0.100 ± 0.527 |
| Cholic acid | 0.156 ± 0.656 | 0.027 ± 0.337 |
| Deoxycholic acid | -0.027 ± 0.288 | -0.039 ± 0.360 |
| Glycochenodeoxycholic acid | -0.564 ± 3.310 | 0.581 ± 4.408 |
| Glycocholic acid | -0.370 ± 2.422 | 2.253 ± 12.291 |
| Glycodeoxycholic acid | -0.516 ± 1.247 | -0.266 ± 2.688 |
| Glycolithocholic acid | -0.0234 ± 0.0762 | -0.0187 ± 0.1768 |
| Lithocholic acid | -0.010 ± 0.047 | -0.003 ± 0.047 |
| Taurochenodeoxycholic acid | -0.085 ± 2.495 | 0.857 ± 3.048 |
| Taurocholic acid | 0.070 ± 2.059 | 1.127 ± 4.380 |
| Taurodeoxycholic acid | -0.0828 ± 0.4412 | -0.0343 ± 0.3683 |
| Taurolithocholic acid | -0.0098 ± 0.0424 | -0.0082 ± 0.0684 |
Blood samples were collected at specified timepoints for assessment of bile acids and biomarkers of bile acid synthesis as measured by C4. Baseline was defined as the last non-missing central value on or before the first dose of the randomized study medication.
| mcg/L | Elafibranor 80 mg | Placebo |
|---|---|---|
| Change From Baseline at Week 52 in Bile Acids and Biomarkers of Bile Acid Synthesis as Measured by 7 Alpha-hydroxy-4-cholesten-3-one (C4) at Week 52 | -7.288 ± 16.779 | -4.044 ± 12.995 |
Blood samples were collected at specified timepoints for assessment bile acids and biomarkers of bile acid synthesis as measured by Fibroblast Growth Factor 19. Baseline was defined as the last non-missing central value on or before the first dose of the randomized study medication.
| pg/mL | Elafibranor 80 mg | Placebo |
|---|---|---|
| Change From Baseline in Bile Acids and Biomarkers of Bile Acid Synthesis as Measured Fibroblast Growth Factor 19 at Week 52 | -12.89 ± 80.24 | 54.54 ± 343.47 |
The PBC Worst Itch NRS is a simple, self-administered PRO questionnaire that measures itch intensity. Participants rate intensity of their worst Itch on an 11-point scale ranging from 0 (no itch) to 10 (worst itch imaginable). Total score ranged from 0 (no itch) to 10 (worst itch imaginable). Higher scores indicated worse outcomes. Response to PBC Worst Itch NRS was according to clinically meaningful change at least 30% reduction; one point, two points or three points decrease in score from baseline in participants with a baseline NRS score ≥4. Baseline was defined as the average of the daily PBC Worst itch scores on available data within 14 days prior the day of randomization. Post-baseline data was defined as the average of the daily PBC Worst itch scores on available data in 4-week period intervals (available data every 28 days after the day of first study drug intake).
| Percentage of participants | Elafibranor 80 mg | Placebo |
|---|---|---|
| Week 24: 30% reduction from baseline | 43.6 | 28.6 |
| Week 52: 30% reduction from baseline | 55.6 | 33.3 |
| Week 24: One-point decrease from baseline | 53.8 | 42.9 |
| Week 52: One-point decrease from baseline | 61.1 | 38.9 |
| Week 24: Two-point decrease from baseline | 38.5 | 28.6 |
| Week 52: Two-point decrease from baseline | 47.2 | 33.3 |
| Week 24: Three-point decrease from baseline | 28.2 | 19.0 |
| Week 52: Three-point decrease from baseline | 41.7 | 33.3 |
The PBC Worst Itch NRS is a simple, self-administered PRO questionnaire that measures itch intensity. Participants rate intensity of their worst Itch on an 11-point scale ranging from 0 (no itch) to 10 (worst itch imaginable). Total score ranged from 0 (no itch) to 10 (worst itch imaginable). Higher scores indicated worse outcomes. Baseline was defined as the average of the daily PBC Worst itch scores on available data within 14 days prior the day of randomization. Post-baseline data was defined as the average of the daily PBC Worst itch scores on available data in 4-week period intervals (available data every 28 days after the day of first study drug intake). A worsening of Pruritus was defined by a positive change from baseline in PBC Worst Itch NRS score greater than 2 at week 24 and 52.
| Percentage of participants | Elafibranor 80 mg | Placebo |
|---|---|---|
| Week 24 | 89.2 | 86.3 |
| Week 52 | 76.7 | 82.6 |
The 5-D Itch scale is a questionnaire that has been validated in several different diseases. It assesses symptoms in terms of 5 domains: duration: score range 1 (less than 6 hours) to 5 (all day); degree: score range 1 (not present) to 5 (unbearable); duration: score range 1 (less than 6 hours) and 5 (all day); direction: score range 1(completely resolved) and 5 (getting worse); disability: score range 1 (never affects or not applicable) and 5 (delays falling asleep and frequently wakes up at night or always affects this activity) and distribution: where the question was to mark where itching is present in body parts over the last two weeks. Participants rated their symptoms over preceding 2-week period on a 1 to 5 scale, with 5 being the most affected. The 5-D Itch total score ranged between 5 (no pruritus) and 25 (most severe pruritus). Higher scores indicated worse outcomes. Baseline= last non-missing value on or before the first dose of the randomized study medication.
| Scores on a scale | Elafibranor 80 mg | Placebo |
|---|---|---|
| Change From Baseline in 5-D Itch at Week 52 | -1.9 (-2.6 to -1.3) | -0.6 (-1.6 to 0.3) |
The PROMIS Fatigue Short Form 7a consists of seven items that measure both the experience of fatigue and the interference of fatigue on daily activities over the past week. Participants completed the PROMIS Fatigue Short Form 7a and answered following questions on a scale from 1 (never) to 5 (always) : "How often did you feel tired"; "How often did you experience extreme exhaustion"; "How often did you run out of energy"; "How often did your fatigue limit you at work"; "How often were you too tired to think clearly"; "How often were you too tired to take a bath or shower" and 'How often did you have enough energy to exercise strenuously". T-score values include mean of 50 and standard deviation of 10. The PROMIS Fatigue T-score ranged from 29.4 (best) to 83.2 (worst). Higher scores indicated worse outcomes. Baseline was defined as the last non-missing value on or before the first dose of the randomized study medication.
| T-score | Elafibranor 80 mg | Placebo |
|---|---|---|
| Change From Baseline in Patient-Reported Outcomes Measurement Information System (PROMIS) Fatigue Short Form 7a at Week 52 | -2.45 (-3.84 to -1.07) | -1.23 (-3.22 to 0.77) |
The ESS is a short, self-administered questionnaire that consists of 8 questions asking to rate how likely it is to fall asleep in everyday situations (each question can be scored from 0 to 3 points; '0' indicates no chance of dozing and '3' indicates high chance of dozing). It provides a total score which has been shown to relate to the participant's level of daytime sleepiness (total score range 0 \[no sleepiness\] to 24 points \[significant sleepiness\]). The total score is the sum of all item scores and ranged from 0 (best) to 24 (worst). Higher scores indicated more chances of sleepiness. Participants were asked to complete the ESS with regard to the level of sleepiness they experienced over approximately the past 7 days. Baseline was defined as the last non-missing value on or before the first dose of the randomized study medication.
| Scores on a scale | Elafibranor 80 mg | Placebo |
|---|---|---|
| Change From Baseline in Epworth Sleepiness Scale (ESS) at Week 52 | -0.3 (-1.1 to 0.5) | -0.5 (-1.7 to 0.6) |
PBC-40 assess symptoms across 6 domains:symptoms,itch,fatigue,cognitive,emotional and social. Participants responded on verbal response scale,depending on section options range from 'never'/'not at all'/'strongly disagree' to 'always'/'very much'/'strongly agree'.5 items (3/3 in itch domain and 2/10 in social domain)also included a 'does not apply' option.Domains:Symptoms(7 questions)score range 7-35,Itch(3 questions)score range 3-15,Fatigue(11 questions)score range 11-55,Cognitive(6 questions)score range 6-30,Emotional(3 questions)score range 3-15,Social(10 questions)score range 10-50.Score for each domain was provided(total score was not calculated),with each verbal response scale correlating to score of 1-5 per item(0-5 on items with a 'does not apply' option);5=most affected.Individual item scores are summed to give total domain score.Higher scores=worse outcomes.PBC-40 had 4-week recall period.Baseline=last non-missing value on or before first dose of randomized study medication.
| Scores on a scale | Elafibranor 80 mg | Placebo |
|---|---|---|
| Symptoms | 0.2 (-0.5 to 0.8) | -0.9 (-1.8 to 0.1) |
| Itch | -1.4 (-1.8 to -0.9) | -0.2 (-0.9 to 0.5) |
| Fatigue | -1.5 (-2.7 to -0.2) | -1.2 (-3.0 to 0.7) |
| Cognitive | -0.6 (-1.4 to 0.2) | -0.7 (-1.8 to 0.4) |
| Emotional | -0.8 (-1.2 to -0.3) | -0.6 (-1.2 to 0.1) |
| Social | -1.1 (-2.3 to 0.1) | -0.4 (-2.1 to 1.3) |
The EQ-5D-5L is a 6-item, standardized questionnaire that assesses mobility, self-care, usual activities, pain/discomfort, anxiety/depression, and overall health state. The visual analog scale (VAS) of EQ-5D-5L questionnaire is numbered from 0 (worst) to 100 (best). Higher scores indicated better outcomes. Baseline was defined as the last non-missing value on or before the first dose of the randomized study medication.
| Scores on a scale | Elafibranor 80 mg | Placebo |
|---|---|---|
| Change From Baseline in Health Utility as Measured by the European Quality of Life 5 Dimensions 5 Level Version (EQ-5D-5L) at Week 52 | 2.5 (0.0 to 4.9) | 1.6 (-1.9 to 5.0) |
DEXA scanning (hip and lumbar) was performed in participants to assess bone mineral density (femoral neck, lumbar and total hip). T-scores were calculated based on actual measured bone density value. The T-score compared a participant's bone density against that of a healthy 30-year-old adult. T-scores were used to determine primary osteoporosis, which exists on its own without any other cause and were divided into 3 categories: low risk, medium risk, and high risk (osteoporosis). T-scores measure the number of minerals in a participant's bone. A participant's level of bone loss was compared to that of a typical, healthy 30-year-old adult. A score ≥-1.0 indicates low risk, medium risk is a score between-2.5 and -1.0, and a high risk/osteoporosis is a score ≤-2.5. A positive change in T-score indicates an improvement in bone mineral density. Baseline was defined as the last non-missing central value on or before the first dose of the randomized study medication.
| T-score | Elafibranor 80 mg | Placebo |
|---|---|---|
| Femoral Neck Bone Mineral Density T-score | -0.016 ± 0.402 | -0.111 ± 0.533 |
| Lumbar Bone Mineral Density T-score | -0.006 ± 0.487 | -0.022 ± 0.405 |
| Total Hip Bone Mineral Density T-score | 0.039 ± 0.529 | -0.371 ± 0.618 |
Blood samples were collected at specified timepoints for assessment of serum markers of bone turnover, CTX. Baseline was defined as the last non-missing central value on or before the first dose of the randomized study medication.
| pg/mL | Elafibranor 80 mg | Placebo |
|---|---|---|
| Change From Baseline in Serum Markers of Bone Turnover Carboxy Terminal Crosslinked Telopeptides of Type 1 Collagen [CTX] at Week 52 | 36.5 ± 212.6 | 44.5 ± 129.7 |
Blood samples were collected at specified timepoints for assessment of serum markers of bone turnover, P1NP. Baseline was defined as the last non-missing central value on or before the first dose of the randomized study medication.
| mcg/L | Elafibranor 80 mg | Placebo |
|---|---|---|
| Change From Baseline in Serum Markers of Bone Turnover Type 1 Procollagen Peptide [P1NP]) at Week 52 | -2.79 ± 32.55 | -5.60 ± 20.03 |
Onset of clinical outcomes were described as a composite endpoint composed of the following: model for end stage liver disease sodium (MELD-Na) \>14 for participants with baseline MELD-Na \<12; liver transplant; uncontrolled ascites requiring treatment; hospitalization for new onset or recurrence of any including, variceal bleed, hepatic encephalopathy defined as West-Haven score of 2 or more and spontaneous bacterial peritonitis; and death.
| Percentage of participants | Elafibranor 80 mg | Placebo |
|---|---|---|
| Meld-Na > 14 while baseline Meld-Na < 12 | 0.9 | 0.0 |
| Liver transplant | 0.0 | 0.0 |
| Uncontrolled ascites requiring treatment | 0.9 | 0.0 |
| Hospitalization for new onset or recurrence of variceal bleed | 0.0 | 0.0 |
| Hospitalization for new onset or recurrence of Hepatic encephalopathy | 0.0 | 0.0 |
| Hospitalization for new onset or recurrence of Spontaneous bacterial peritonitis | 0.0 | 0.0 |
| Death | 0.9 | 0.0 |
An AE was any untoward medical occurrence in a participant or clinical investigation participant who was administered an investigational product, and which does not necessarily have a causal relationship with treatment. A TEAE was defined as any AE with onset during TEAE assessment period, or any event started prior to first dose of treatment and worsened or became serious during the TEAE assessment period. An SAE was any AE that resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital abnormality/birth defect. An AESI was an AE that might not be serious but was of special importance to a particular treatment or class.
| Participants | Elafibranor 80 mg | Placebo |
|---|---|---|
| TEAEs | 104 | 48 |
| TESAEs | 11 | 7 |
| AESIs | 32 | 14 |
Blood samples were collected at specified timepoints to evaluate plasma concentration of Elafibranor and its metabolite GFT1007.
| Nanograms per milliliter (ng/mL) | Elafibranor 80 mg |
|---|---|
| Elafibranor: Week 4: Pre-dose | 92.7 ± 52.9 |
| Elafibranor: Week 4: 0.5 hour post-dose | 408.2 ± 104.1 |
| Elafibranor: Week 4: 1.5 hours post-dose | 281.7 ± 66.1 |
| Elafibranor: Week 4: between 2-3 hours post-dose | 182.0 ± 67.8 |
| Elafibranor: Week 4: 4 hours post-dose | 127.7 ± 52.7 |
| Elafibranor: Week 4: 6 hours post-dose | 117.1 ± 53.5 |
| GFT1007: Week 4: Pre-dose | 77.3 ± 85.6 |
| GFT1007: Week 4: 0.5 hour post-dose | 894.6 ± 150.0 |
| GFT1007: Week 4: 1.5 hours post-dose | 1707.2 ± 52.1 |
| GFT1007: Week 4: between 2-3 hours post-dose | 1160.8 ± 53.9 |
| GFT1007: Week 4: 4 hours post-dose | 655.8 ± 54.7 |
| GFT1007: Week 4: 6 hours post-dose | 375.7 ± 65.9 |
Collected over Treatment-emergent adverse events (TEAEs) were reported from the start of study treatment administration (Day 1) up to DCO date of 01 June 2023, approximately 980 days.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Elafibranor 80 mg | 2/108 (1.9%) | 11/108 (10.2%) | 103/108 (95.4%) |
| Placebo | 0/53 (0%) | 7/53 (13.2%) | 47/53 (88.7%) |
| Event | Elafibranor 80 mg | Placebo |
|---|---|---|
| Acute kidney injuryRenal and urinary disorders | 3/108 | 1/53 |
| COVID-19Infections and infestations | 0/108 | 1/53 |
| Urinary tract infectionInfections and infestations | 0/108 | 1/53 |
| Procedural painInjury, poisoning and procedural complications | 0/108 | 1/53 |
| SyncopeNervous system disorders | 0/108 | 1/53 |
| PainGeneral disorders | 0/108 | 1/53 |
| CataractEye disorders | 0/108 | 1/53 |
| Invasive ductal breast carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/108 | 1/53 |
| Papillary thyroid cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/108 | 1/53 |
| AnxietyPsychiatric disorders | 0/108 | 1/53 |
| Event | Elafibranor 80 mg | Placebo |
|---|---|---|
| COVID-19Infections and infestations | 31/108 | 19/53 |
| PruritusSkin and subcutaneous tissue disorders | 22/108 | 14/53 |
| Abnormal weight gainMetabolism and nutrition disorders | 21/108 | 10/53 |
| Urinary tract infectionInfections and infestations | 12/108 | 9/53 |
| FatigueGeneral disorders | 10/108 | 7/53 |
| Back painMusculoskeletal and connective tissue disorders | 4/108 | 6/53 |
| HeadacheNervous system disorders | 9/108 | 6/53 |
| DiarrhoeaGastrointestinal disorders | 12/108 | 5/53 |
| NauseaGastrointestinal disorders | 12/108 | 3/53 |
| VomitingGastrointestinal disorders | 12/108 | 1/53 |
The Intent-to-treat (ITT) population included all randomized participants.
| Age, Continuous(Years) | Elafibranor 80 mg | Placebo | Total |
|---|---|---|---|
| Mean | 57.5 ± 8.4 | 56.4 ± 9.3 | 57.1 ± 8.7 |
| Sex: Female, Male(Participants) | Elafibranor 80 mg | Placebo | Total |
|---|---|---|---|
| Female | 102 | 52 | 154 |
| Male | 6 | 1 | 7 |
| Race/Ethnicity, Customized(Participants) | Elafibranor 80 mg | Placebo | Total |
|---|---|---|---|
| White | 101 | 46 | 147 |
| Black or African American | 2 | 0 | 2 |
| Asian | 1 | 3 | 4 |
| American Indian or Alaska Native | 0 | 1 | 1 |
| Other | 3 | 2 | 5 |
| Not Reported | 1 | 1 | 2 |
Showing the first 100 of 115 sites across 14 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, annotated case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of study participants.
Time frame: Where applicable, data from eligible studies are available 6 months after the studied medicine and indication have been approved in the US and/or EU.
Access criteria: Further details on Ipsen's sharing criteria and process for sharing are available here (https://www.ipsen.com/science/clinical-trials/clinical-data-transparency/).
Data sharing details ↗ · www.ipsen.com
Ran from Sep 2020 to primary completion in Jun 2023, 32 months.
Results were first posted in Sep 2024, 1 year 3 months after primary completion. A results delay was requested in May 2024.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Elifibranor